Research Institute of Texas / Memorial SloanKettering Cancer Center / /
IndustryTerm
Cancer Prevention / immune systems / select / cancer therapies / therapies for cancer / social media entrepreneurs / /
MedicalCondition
cancers / tumor / late-stage melanoma / cancer / lymphoma / tumors / prostate cancers / melanoma / immune-mediated cancer / breast cancer / /
MedicalTreatment
cancer therapies / immunotherapy / /
Organization
National Foundation for Cancer Research / Cancer Prevention and Research Institute of Texas / Memorial SloanKettering Cancer Center in New York / U.S. Food and Drug Administration / MedImmune’s Oncology Innovative Medicines Unit / Koch Center for Applied Research of Genitourinary Cancers / /
Person
Ferran Prat / Padmanee Sharma / Patrick Hwu / Jim Allison / Ed Bradley / /
Position
scientific director / Economist / platform Scientific Director / senior vice president and head / leader / executive director / director of the moon shots / deputy director of the David / vice president for strategic industry ventures / Vivian L. Smith Distinguished Chair / executive director of the immunotherapy platform / chair / Established Investigator / associate professor / chair of Melanoma Medical Oncology / /
MD Anderson, MedImmune join forces on immunotherapy Friday, March 14, 2014 Jim Allison, Ph.D., is executive director of the immunotherapy platform. MD Anderson and MedImmune, the global biologics research and development